David T. Rovee, 54 years old, was named president, chief operating officer and a director of this biotechnology company.
Mr. Rovee, who had been vice president for research and development, succeeds Thomas M. Tully, 48, who resigned to pursue other opportunities.
Mr. Rovee was also named chief scientific officer.
Also, Michael T. Pieniazek, chief financial officer, was named to the added post of executive vice president.
